23 / 45
Pembrolizumab en TNBC
23
mTNBC
•
KEYNOTE-086 Cohort B: Pembrolizumab Monotherapy for PD-
L1–Positive, Previously Untreated, Metastatic Triple-Negative
Breast Cancer
•
KEYNOTE-119: A Randomized Phase 3 Study of Single-Agent
Pembrolizumab Versus Single-Agent Chemotherapy per
Investigator’s Choice for Metastatic Triple-Negative Breast
Cancer
•
KEYNOTE-355: Randomized, Double-Blind, Phase III Study of
Pembrolizumab Plus Chemotherapy Versus Placebo Plus
Chemotherapy for Previously Untreated, Locally Recurrent
Inoperable or Metastatic Triple-Negative Breast Cancer
Neoadjuvant
KEYNOTE-173: Phase Ib Multicohort
Study of Pembrolizumab in Combination
With Chemotherapy as Neoadjuvant
Treatment for Triple-Negative Breast
Cancer
Neoadjuvant/Adjuvant
KEYNOTE-522: Phase III, Study of
Pembrolizumab + Chemotherapy as
Neoadjuvant followed by Pembrolizumab
vs Placebo as Adjuvant Therapy for
Triple-Negative Breat Cancer
Early Stage
Locally Recurrent
Inoperable and
Metastatic Disease